Irinotecan, Capecitabine and Avastin for Metastatic Colorectal Cancer as Salvage Treatment

Sponsor
University Hospital of Crete
Study ID
NCT00717990
Phase
PHASE2
Status
Terminated

Conditions

  • Metastatic Colorectal Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - 72 Years
Healthy Volunteers
Not accepted

Interventions

  • Capecitabine — DRUG
    Capecitabine 2000 mg/m2 p.o. daily, for days 1-14, every 3 weeks for 6 cycles
  • Bevacizumab — DRUG
    Bevacizumab 7.5 mg/kg intravenous (IV) on day 1 every 3 weeks for 6 cycles
  • Irinotecan — DRUG
    Irinotecan 250 mg/m2 IV on day 1 every 3 weeks for 6 cycles

Study Details

This study will evaluate the efficacy of Irinotecan,Capecitabine and Avastin combination in patients with no response to previous treatment with 5-Fluorouracil,Leucovorin,Eloxatin and Avastin.

Key Dates

Start date
Apr 30, 2008
Status verified
Oct 2015
Primary completion
Dec 31, 2012
Completion
Dec 31, 2012

Study Design

Enrollment
15 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: 1
    XELIRI/Avastin

Primary Outcome Measure

Objective Response Rate [ Time Frame: up to 6 months ]

Related Studies